Next week, massive premium increases get locked in. The GOP has shown no interest in stopping it, or preventing any other increases in health care costs.
Big Pharma
Posted inEconomic Policy
Meet the Connectors
Middlemen, our economy’s most shadowy characters, sit in between buyers and sellers and get rich in the process. It can even be a matter of life or death.
Posted inPolitics
Rule by Deal
Donald Trump engages in ad hoc agreements with individual companies and governments to expand his power. Some observers have described these actions as a new “economic nationalism”—but that term fails to explain what makes this administration’s decision-making unique.
Posted inTAP
Just Plain Everyday American Socialism
Socialist programs that come from non-socialists, like California Gov. Gavin Newsom’s low-cost insulin production program, don’t arouse the same level of right-wing hysteria. They also don’t arouse the same level of left-wing enthusiasm.
Posted inHealth and Social Policy
‘TrumpRx’ Is Another Pretend Solution for High Drug Prices
The proposed government website will just refer people to the drug companies, which use direct-to-consumer pricing to distract from continued high profits.
Posted inPolitics
Trump Appointees Are Hijacking the Patent System
Cronyism is threatening American innovation.
Posted inHealth and Social Policy
Trump’s Order to Cut Drug Prices Would Raise Drug Prices
The so-called ‘pill penalty’ fix is a corporate favor designed to increase the period where prescriptions are immune from price negotiations.
Posted inLaw and Justice
The Case Without a Judge
The logical, absurd end point of Donald Trump’s government smash-and-grab
Posted inMoney, Politics, and Power
L.A. Times Owner Has Financial Motivations for Boosting RFK Jr.
Dr. Patrick Soon-Shiong’s biotech firm is preparing three applications needing approval from the Food and Drug Administration.
Posted inHealth and Social Policy
Trump’s Big Choice on Drug Prices
By following through on Biden’s Medicare price negotiation program, he can take credit for prescription reductions. But Big Pharma doesn’t want that to happen.